Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The analysis of the quarterly financial ratios reveals several notable trends in asset and equity efficiency over the reported periods.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio, available from the first quarter of 2021 onwards, shows a consistent upward trend. It increased from 6.47 in March 2021 to a peak of 9.51 in September 2024, before slightly declining to 8.57 by March 2025. This indicates an improving efficiency in utilizing fixed assets to generate sales over time, with some minor fluctuations towards the end of the period.
- Net Fixed Asset Turnover (Including Operating Lease, Right-of-Use Asset)
- This adjusted ratio exhibits a different pattern. Starting at 4.83 in March 2021, it increased gradually, peaking at 6.86 in June 2023. However, from this point onward, the ratio declined quite sharply to values around 4.21-4.26 by the end of 2024 and early 2025. This suggests that when including operating leases and right-of-use assets, the company's efficiency in generating sales from these combined assets improved initially but deteriorated significantly in the latter part of the timeline.
- Total Asset Turnover
- The total asset turnover ratio demonstrates a generally declining trend through the periods. It started at 0.53 in March 2021 and gradually decreased to lows near 0.43 by the end of 2023. Although there is some recovery in 2024, it remains below earlier levels, hovering around 0.48 to 0.49. This trend indicates a reduction in overall efficiency in generating revenue from total assets over time, with a small rebound in the most recent quarters.
- Equity Turnover
- Equity turnover also follows a downward trajectory, starting at 0.71 in March 2021 and declining steadily to around 0.55 by December 2023. A slight improvement occurs in 2024, with the ratio rising to approximately 0.67 by March 2025. This reveals a reduced efficiency in using shareholders' equity to produce revenue during most of the period, partially recovering towards the end.
In summary, the company shows improved utilization of fixed assets (excluding leased assets) to drive sales, whereas the inclusion of leased assets depicts a less favorable trend in later periods. Meanwhile, overall and equity-related asset turnovers have decreased over time, suggesting challenges in converting the broader asset and equity base into revenues, with modest recovery observed near the end of the timeline.
Net Fixed Asset Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Property and equipment, net | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Net fixed asset turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net fixed asset turnover
= (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The revenue figures exhibit a consistent upward trend over the observed periods. Starting at approximately $1.52 billion in the first quarter of 2020, revenues gradually increase, reaching a peak near $2.91 billion by the fourth quarter of 2024. There is a notable acceleration in revenue growth from mid-2021 onwards, with occasional minor fluctuations, yet the overall direction remains positive. The data suggests sustained demand or successful expansion initiatives contributing to progressive revenue enhancement.
Regarding property and equipment net values, the amounts show a gradual increase with some variability. Beginning at roughly $736 million in the first quarter of 2020, the asset base grows steadily, rising to approximately $1.30 billion by the end of the period in the first quarter of 2025. Despite slight declines in a few quarters, the general pattern indicates incremental investment or capitalization of property and equipment assets, consistent with capacity expansion or maintenance efforts.
The net fixed asset turnover ratio, available starting from the fourth quarter of 2020, reflects improving efficiency in the utilization of fixed assets to generate revenue. The ratio begins at 6.47 and generally trends upward, peaking near 9.51 in the third quarter of 2024 before slightly declining. This increase suggests enhanced operational productivity or more effective deployment of fixed assets over time, correlating with the firm's rising revenues and growing asset base.
- Revenue Trend
- Steadily increasing from $1.52 billion in early 2020 to $2.91 billion by late 2024, indicating robust business growth.
- Property and Equipment, Net
- Gradual rise from $736 million to approximately $1.30 billion, reflecting ongoing investment in fixed assets.
- Net Fixed Asset Turnover Ratio
- Improvement from 6.47 to a peak of 9.51, showing enhanced efficiency in asset utilization although slight decrease near the end.
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + )
÷ =
- Revenues
- Revenues exhibited a consistent upward trend over the analyzed period. Starting from approximately $1.52 billion in March 2020, revenues increased steadily each quarter, reaching a peak above $2.9 billion in December 2024. Although there was a slight decrease in the final recorded quarter ending March 2025 to about $2.77 billion, the overall trajectory remained positive, reflecting sustained growth.
- Property and Equipment, Net
- The net value of property and equipment, including operating lease right-of-use assets, showed a general upward trend with some fluctuations. Beginning at around $736 million in March 2020, the value increased notably reaching approximately $1.28 billion by December 2020 and continued rising gradually thereafter. A significant acceleration occurred from June 2024 onwards, with values increasing steeply to about $2.63 billion by March 2025, indicating substantial investment or acquisition of fixed assets in the latter part of the period.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio started being reported in December 2020 at 4.83 and generally improved over subsequent quarters, peaking at 6.86 in June 2024. This ratio measures how efficiently the company used its net fixed assets to generate revenue. The increase suggests improved asset utilization efficiency over time. However, after reaching its highest point, the ratio declined sharply to around 4.2 by March 2025, which may imply a relative decrease in revenue generation efficiency from the fixed asset base or a lag in revenue growth compared to the rise in asset investment towards the end of the observation period.
Total Asset Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Total asset turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Total asset turnover
= (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues exhibit a steady upward trend over the observed period, increasing from approximately $1.52 billion in Q1 2020 to a peak near $2.91 billion in Q4 2024. Despite some fluctuations, the general trajectory shows consistent growth, with revenues nearly doubling over the five-year span. There is a noticeable acceleration in revenue gains starting around Q2 2021, maintaining elevated levels through to early 2025. However, the final recorded quarter (Q1 2025) shows a slight decline compared to the preceding quarter.
- Total Assets Patterns
- Total assets follow an overall increasing trend, rising from about $8.9 billion in Q1 2020 to over $22.8 billion by Q1 2025. This steady asset growth indicates ongoing expansion or increased capital investment. Notably, total assets saw a pronounced increment between 2022 and early 2024, exceeding $20 billion for the first time around Q2 2023. There is a moderate dip visible in mid-2024 before assets rise again, suggesting potential asset reallocation or divestment activities.
- Total Asset Turnover Analysis
- The total asset turnover ratio, available from Q3 2020 onward, generally demonstrates a declining pattern. Starting at 0.53 in Q3 2020 and Q4 2020, it peaks briefly at 0.57 in Q4 2021 before trending downward to a low near 0.43 by Q4 2023. A temporary recovery occurs in 2024, with the ratio climbing to 0.51 in Q1 2024, but it stabilizes around 0.48–0.49 by early 2025. This trend suggests that while assets have increased, revenue growth has not kept pace proportionally, possibly indicating decreased efficiency in asset utilization over time.
- Summary Insights
- The combined analysis reveals that the company has experienced substantial growth in both revenues and total assets over the five-year horizon. However, the declining asset turnover ratio signals that despite rising sales, the efficiency with which the company employs its assets to generate revenue is diminishing. This could imply increased capital intensity, expansion into asset-heavy operations, or temporary inefficiencies. Careful management of asset deployment and operational efficiency may be warranted to sustain growth momentum and improve asset productivity.
Equity Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Equity turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Equity turnover
= (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
÷ Shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenues
- The quarterly revenues exhibit a generally upward trend from March 31, 2020, through March 31, 2025. Starting at approximately 1.52 billion USD in early 2020, revenues increase steadily with minor fluctuations, reaching a peak of around 2.91 billion USD in December 2024. There is a notable growth phase between mid-2020 and late 2021, where revenues rose from about 1.52 billion USD to over 2.07 billion USD. After a brief plateau and slight declines in late 2022 and early 2023, revenues resume growth in late 2023 through early 2025, although the quarter ending March 2025 shows a slight contraction compared to the previous quarter.
- Shareholders’ Equity
- Shareholders’ equity consistently increases from approximately 6.46 billion USD at the end of Q1 2020 to a peak near 17.58 billion USD in late 2023. This represents a substantial expansion of equity over the period, reflecting accumulated retained earnings or capital injections. A decline occurs around mid-2024, dropping from about 18.55 billion USD in March 2024 to roughly 14.77 billion USD in June 2024. Subsequently, equity recovers gradually, reaching approximately 16.50 billion USD by March 2025. This interruption in the equity trend may indicate significant equity adjustments, asset disposals, or other corporate actions impacting net equity.
- Equity Turnover Ratio
- The equity turnover ratio, available from September 2020 onwards, displays a gradual decline over time from an initial 0.71 down to a low near 0.55 by December 2023. This decline suggests that revenue generation relative to equity is diminishing, potentially indicating increasing equity bases or a relative slowdown in revenue efficiency. Notably, in late 2024, the ratio experiences a temporary rise to around 0.7 before stabilizing near 0.67 by the first quarter of 2025. This partial recovery may reflect enhanced operational efficiency or a change in capital structure impacting revenue leverage.
- Key Insights and Implications
- Overall, the data reveal steady revenue growth over the five-year horizon, supporting continued business expansion. The substantial increase in shareholders' equity indicates strengthening financial foundations, albeit with a period of marked equity decline in mid-2024 suggesting possible strategic or financial restructuring. The decreasing trend in equity turnover ratio highlights that the company is generating less revenue per unit of equity over much of the timeframe, although slight improvements toward the end may demonstrate enhanced asset utilization. Monitoring equity fluctuations and turnover ratios going forward will be important for assessing capital efficiency and return on equity metrics.